1. Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV. (22nd October 2022) Authors: Ciccullo, A; Baldin, G; Borghi, V; Cossu, M V; Giacomelli, A; Lagi, F; Farinacci, D; Iannone, V; Passerotto, R A; Capetti, A; Sterrantino, G; Mussini, C; Antinori, S; Di Giambenedetto, S Journal: Journal of antimicrobial chemotherapy Issue: Volume 78:Number 1(2023) Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗